Research advances on haploidentical hematopoietic stem cell transplantation in the treatment of severe aplastic anemia in children.
10.7499/j.issn.1008-8830.2105073
- Author:
Yang-Yang GAO
1
;
Xiao-Juan CHEN
1
;
Rong-Mu LUO
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
- Publication Type:Review
- Keywords:
Child;
Conditioning regimen;
Donor-specific anti-HLA antibody;
Haploidentical hematopoietic stem cell transplantation;
Poor graft function;
Severe aplastic anemia
- MeSH:
Anemia, Aplastic/therapy*;
Child;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Transplantation Conditioning;
Transplantation, Homologous
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(8):854-859
- CountryChina
- Language:English
-
Abstract:
Haploidentical hematopoietic stem cell transplantation is a recommended alternative therapy for children with severe aplastic anemia who lack a human leukocyte antigen (HLA)-identical sibling donor and do not respond well to immunosuppressive therapy; however, due to non-identical HLA, the patients may have donor-specific anti-HLA antibody, which may lead to a relatively high incidence rate of poor graft function. Compared with HLA-identical transplantation, conditioning regimen for haploidentical transplantation still needs to be explored. This article reviews the detection and treatment of donor-specific anti-HLA antibody, the selection of conditioning regimen, and the mechanism and treatment of poor graft function in haploidentical hematopoietic stem cell transplantation.
